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Cyclophilin A (Cyp A) binds the human immunodeficiency virus type 1 (HIV-1) capsid (CA) protein and contributes to the early events in
virus replication in some cells. The retroviral restriction factor TRIM5α can inhibit the early, post-entry phase of infection by associating with the
incoming viral capsid. Cyp A has been proposed to prevent restriction factor binding in human cells, thus enhancing HIV-1 infectivity, and to
potentiate restriction of HIV-1 in monkey cells. Here we show that the positive effects of Cyp A–CA binding on HIV-1 infectivity do not depend
on human TRIM5α. Disruption of Cyp A binding to CA partially relieved the block to HIV-1 infection imposed by several TRIM5α variants, but
Cyp A–CA binding was not absolutely required for TRIM5α antiviral activity. Inhibition of Cyp A function by cyclosporine significantly
decreased the efficiency of TRIM5α-mediated restriction only when the restricted virus capsid interacted with Cyp A.
© 2006 Elsevier Inc. All rights reserved.Keywords: Cyclophilin; Cyclosporine; Immunophilin; Rapamycin; Retrovirus; TRIM5; Restriction factor; Human immunodeficiency virusIntroduction
The immunophilin cyclophilin A (Cyp A) binds to a flexible,
proline rich loop in the N-terminal domain of the human
immunodeficiency virus type 1 (HIV-1) capsid (CA) and
contributes to the efficient infection of some human cells
(Braaten and Luban, 2001; Franke et al., 1994; Gamble et al.,
1996; Gitti et al., 1996; Luban et al., 1993; Thali et al., 1994).
Cyp A is a cytosolic, ubiquitously expressed enzyme that can
catalyze the cis/trans-isomerization of prolyl peptide bonds
(Fischer et al., 1984, 1989; Galat, 2003). Cyp A binds glycine
89-proline 90 in the HIV-1 CA, and changes in these residues
that disrupt Cyp A association cause a significant decrease in the
efficiency ofHIV-1 replication in some human cells (Braaten and
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doi:10.1016/j.virol.2006.03.015HIV-1 CA and Cyp A can also be disrupted by cyclosporine A
(CsA), an immunosuppressive drug that competitively binds to
the Cyp A active site (Braaten et al., 1996a; Luban et al., 1993).
Capsids from some retroviruses, such as simian immunodefi-
ciency virus (SIVmac) and the gammaretrovirus murine leukemia
virus (MLV), do not bind Cyp A; Cyp A expression in the host
cell is not necessary for successful infection by these viruses
(Franke et al., 1994; Thali et al., 1994).
The role of Cyp A during HIV-1 infection remains to be fully
elucidated. Cyp A is necessary for an early, post-entry step in the
target cell (Braaten et al., 1996b; Sokolskaja et al., 2004).
Preventing the binding of Cyp A to the HIV-1 CA protein, either
by treatment of virions with CsA or by altering CA to abolish
Cyp A binding, leads to defects in the accumulation of reverse
transcripts (Braaten et al., 1996b). Some reports have suggested
that Cyp A facilitates the disassembly of the HIV-1 capsid
complex by catalyzing the cis/trans-isomerization of the gly
89-pro 90 peptide bond (Bosco and Kern, 2004; Bosco et al.,
2002; Howard et al., 2003). Others have suggested that Cyp
A protects the HIV-1 capsid from an antiviral activity in
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Towers et al., 2003).
The species-specific tropism of a particular retrovirus can be
determined by dominant host factors that recognize the
incoming capsid (Bieniasz, 2004; Goff, 2004). One of these
factors, TRIM5α, restricts HIV-1 infection in Old World
monkey cells (Stremlau et al., 2004). The TRIM5 gene encodes
at least three isoforms; the longest isoform, TRIM5α, is the only
one that possesses a C-terminal B30.2 domain and exhibits
antiviral activity (Hatziioannou et al., 2004b; Keckesova et al.,
2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al.,
2004). Variation in TRIM5α protein sequences among different
primate species accounts for the observed patterns of species-
specific restrictions to retrovirus infections (Song et al., 2005a,
2005b). For example, rhesus monkey TRIM5α (TRIM5αrh), an
Old World monkey TRIM5α protein, potently blocks HIV-1 but
only modestly restricts SIVmac (Stremlau et al., 2004). In
contrast, TRIM5α proteins from New World monkeys restrict
SIVmac but not HIV-1 (Song et al., 2005a, 2005b). One
exceptional New World monkey, the owl monkey, expresses a
TRIM5α-Cyp A fusion protein (TRIMCyp) that inhibits
infection by HIV-1 (Nisole et al., 2004; Sayah et al., 2004).
The block to HIV-1 in these cells can be overcome by changes
in the HIV-1 CA protein that abolish Cyp A binding or by
treatment of the target cell with CsA (Nisole et al., 2004; Sayah
et al., 2004; Towers et al., 2003).
Human TRIM5α (TRIM5αhu) fails to restrict SIVmac but
partially inhibits HIV-1 (Hatziioannou et al., 2004b; Keckesova
et al., 2004; Stremlau et al., 2004; Yap et al., 2004). However,
expression of TRIM5αhu potently inhibits infection by N-tropic
MLV (N-MLV) (Hatziioannou et al., 2004b; Keckesova et al.,
2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al.,
2004). The determinants of antiviral potency in TRIM5αhu have
been mapped to the B30.2 domain (Nakayama et al., 2005;
Perez-Caballero et al., 2005; Sawyer et al., 2005; Stremlau et
al., 2005; Yap et al., 2005). A single amino acid change in
TRIM5αhu, R332P, increases the anti-HIV-1 activity to a level
comparable to that of TRIM5αrh (Stremlau et al., 2005; Yap et
al., 2005). Surprisingly, this change also confers the ability on
TRIM5αhu to restrict SIVmac (Stremlau et al., 2005).
The viral determinants for restriction map to CA, suggesting
that TRIM5α associates either directly or indirectly with CA
(Hatziioannou et al., 2003; Kootstra et al., 2003; Munk et al.,
2002; Owens et al., 2003; Stevens et al., 2004). Changes in the
Cyp A-binding loop of the HIV-1 CA can allow partial escape
from TRIM5α (Kootstra et al., 2003; Hatziioannou et al.,
2004a; Owens et al., 2004); however, at least one report has
shown that an alteration of glycine 89 in CA does not lead to
any enhancement of HIV-1 infection in a rhesus monkey kidney
cell line (Towers et al., 2003). Recently, TRIM5α proteins from
Old World monkeys have been shown to bind specifically to
assembled HIV-1 capsid complexes; expression of a restricting
TRIM5α protein in otherwise susceptible cells is associated
with the accelerated disassembly of the capsid of the restricted
virus (Stremlau et al., in press).
To date, cofactors necessary for TRIM5α antiviral activity
have not been reported. The involvement of Cyp A andTRIM5α during early, post-entry events in retroviral infection
suggests that their activity may be linked. Both TRIM5α and
Cyp A associate with the HIV-1 CA, and reverse transcripts fail
to accumulate in either TRIM5α-restricted cells or in some
human cells where the interaction between Cyp A and CA has
been disrupted (Besnier et al., 2002; Braaten et al., 1996b;
Hatziioannou et al., 2003; Munk et al., 2002; Perron et al., 2004;
Stremlau et al., 2004). It has been suggested that the positive
effects of Cyp A on HIV-1 infection in human cells are a
consequence of Cyp A blocking the binding of the TRIM5αhu
restriction factor to the HIV-1 capsid (Towers et al., 2003; Sayah
and Luban, 2004; Sokolskaja et al., 2004). In contrast to the
generally positive effects of Cyp A on HIV-1 replication in
human cells, disrupting Cyp A–CA binding results in increased
HIV-1 infectivity in some monkey cells; indirect evidence
suggests that TRIM5-like restriction factors may be involved in
this effect (Berthoux et al., 2004; Owens et al., 2004; Towers
et al., 2003). It has even been suggested that Cyp A might be
required for TRIM5α-mediated resistance to HIV-1 infection
in Old World monkey cells (Berthoux et al., 2005). Here we
examine possible connections between Cyp A and TRIM5α.
We investigate the restriction activity of TRIM5α variants in
settings where Cyp A–capsid interaction is prevented or does
not occur. We also examined effects of Cyp binding on HIV-1
infection in cells that express or lack TRIM5αhu.
Results and discussion
Effects of cyclosporine A (CsA) treatment on TRIM5α antiviral
potency
CsA is an 11-amino acid cyclic peptide that competitively
inhibits the interaction between Cyp A and the HIV-1 CA
(Franke et al., 1994; Thali et al., 1994). We used CsA to test the
requirement for Cyp A in HIV-1 restriction by TRIM5α. Human
cells that stably express TRIM5αrh or control cells transduced
with the empty pLPCX vector were treated with CsA and
incubated with a VSV G-pseudotyped HIV-1-GFP vector (HIV-
1-GFP). CsA treatment of the control cells did not significantly
affect the efficiency of HIV-1-GFP infection in these cells
compared to that seen in untreated cells (Fig. 1A). This result
was consistent with previous findings (Hatziioannou et al., 2005;
Owens et al., 2004). In contrast, CsA treatment of TRIM5αrh-
expressing cells enhanced HIV-1-GFP infection compared to
that seen in untreated cells expressing TRIM5αrh (Fig. 1A). The
partial relief of HIV-1 restriction in TRIM5αrh cells was more
obvious when HIV-1-GFP infection was carried out at a high
multiplicity of infection (m.o.i.) (Fig. 1A). Thus, Cyp A can
enhance the TRIM5αrh-mediated block to HIV-1 infection;
however, TRIM5αrh can still restrict HIV-1 infection even when
the interaction between Cyp A and CA is blocked by CsA.
The HIV-1 restricting activities of some TRIM5α variants
depend strongly on Cyp A
HeLa cells that stably overexpress TRIM5αhu exhibit a
modest restriction of HIV-1 infection (Hatziioannou et al.,
Fig. 1. Cyclosporine A (CsA) partially abrogates TRIM5α-mediated restriction of HIV-1. (A) HeLa cells were transduced with an empty control vector or vectors
expressing wild-type TRIM5αrh, wild-type TRIM5αhu, the TRIM5αhu mutants K324N and R332P, or the human/rhesus TRIM5α chimera H(R323–332). The cells
were incubated for 2 h in the presence of 0.1% ethanol or 5 μMCsA and then either 4 kcpm or 16 kcpm RT units of HIV-1-GFP were added. (B) The experiment was
carried out as described in panel A except that either 1 kcpm or 8 kcpm RT units of SIVmac-GFP were added to the cells. (C) TE671 cells were incubated for 2 h with
0.1% EtOH or 5 μMCsA before the addition of either N-MLV, B-MLV, or NB-MLV vectors expressing GFP at various dilutions. The percentage of GFP-positive cells
was determined by FACS. The experiment was repeated with similar results.
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determinants of HIV-1 antiviral potency have been mapped to
the B30.2 domain of TRIM5α (Perez-Caballero et al., 2005;
Stremlau et al., 2005; Yap et al., 2005). Replacing residues
323–332 in TRIM5αhu with the corresponding sequence from
TRIM5αrh generates a chimeric protein, H(R323–332), that
possesses anti-HIV-1 potency that is nearly equivalent to that of
wild-type TRIM5αrh (Stremlau et al., 2005). Two single amino
acid changes in the B30.2 domain of TRIM5αhu, K324N and
R332P, also dramatically enhance the ability of TRIM5αhu to
restrict HIV-1 (Stremlau et al., 2005; Yap et al., 2005). Using
CsA, we assessed the role of Cyp A in HIV-1 restriction in
human cells expressing wild-type TRIM5αhu or the three
TRIM5α variants described above. As previously reported
(Perron et al., 2004), CsA treatment of HeLa cells stablyexpressing TRIM5αhu did not significantly increase or decrease
the level of HIV-1-GFP infection compared to that seen in
untreated cells (Fig. 1A). However, the antiviral potency of each
of the TRIM5α variants was significantly diminished in the
presence of CsA, particularly when the cells were challenged at
a higher m.o.i. Thus, the TRIM5α variants exhibit a stronger
dependence on Cyp A for efficient HIV-1 restriction than wild-
type TRIM5αrh.
TRIM5α restriction of SIVmac does not depend on Cyp A
Cyp A does not bind to the SIVmac CA protein and SIVmac
replication is not affected by CsA treatment (Braaten et al., 1996c;
Bukovsky et al., 1997; Franke et al., 1994; Thali et al., 1994).
Neither TRIM5αrh nor TRIM5αhu potently restrict SIVmac
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TRIM5αrh, TRIM5αhu, K324N, R332P, or H(R323–332) with
CsA and then challenged them with SIVmac-GFP. We observed
a slight enhancement of SIVmac infection after CsA treatment
in all the cell lines tested, including cells expressing
TRIM5αhu R332P (Fig. 1B). Even at a high m.o.i. of SIVmac
infection, the addition of CsA to cells stably expressing R332P
did not significantly relieve the restriction. Apparently, Cyp A
enhances the antiviral potency of TRIM5α R332P in a manner
dependent on the targeted virus. One viral property potentially
relevant to this effect is the ability of the viral capsid to bind
Cyp A.
We observed no effect of CsA treatment on the TRIM5αhu-
mediated restriction of N-MLV, which does not interact with
Cyp A. Human TE671 cells restrict N-MLV but not B-MLVor
the dual-tropic NB-MLV (Hatziioannou et al., 2004b; Perron et
al., 2004; Towers et al., 2000, 2003). N-MLV restriction in
TE671 cells was not relieved by the addition of CsA (Fig. 1C).
This result is consistent with the possibility that Cyp A must
interact with the viral capsid to enhance TRIM5α-mediated
restriction.
Effects of CsA treatment on different TRIM5α species variants
In general, TRIM5α variants from Old World monkey cells
potently restrict HIV-1 but not SIVmac infection; New World
monkey TRIM5α variants potently restrict SIVmac but not HIV-
1 infection (Song et al., 2005a, 2005b). Two exceptions are a
TRIM5/Cyclophilin A fusion protein (TRIM-Cyp) from owl
monkeys, a New World monkey species, that restricts HIV-1,
and TRIM5α from spider monkeys (TRIM5αsp), another New
World monkey, that restricts both HIV-1 and SIVmac (Nisole et
al., 2004; Sayah et al., 2004; Song et al., 2005b). To investigate
further the role of Cyp A in TRIM5α restriction, we treated
human cells that stably express various Old World and New
World monkey TRIM5α variants with CsA and infected them
with HIV-1 or SIVmac. HIV-1 restriction in non-permissive cells
could be partially relieved by CsA treatment regardless of the
species origin of the restricting TRIM5α variant (Fig. 2); for
example, the block to HIV-1 infection resulting from theFig. 2. CsA partially relieves restriction of HIV-1 but not SIVmac by TRIM5α from d
expressing TRIM5αrh, TRIM5αhu, TRIM5αAGM(pyg), TRIM5αAGM(tan), TRIM5αsq, o
and then infected with HIV-1-GFP or SIVmac-GFP. The percentage of GFP-positi
comparable results. The results of a typical experiment are shown.expression of TRIM5αrh, TRIM5αAGM(pyg), TRIM5αAGM(tan),
or TRIM5αsp was partially relieved by CsA treatment. SIVmac
infection, even in the control cells expressing the empty
pLPCX vector, exhibited a 2–3-fold increase in efficiency
after CsA treatments (Fig. 2). However, SIVmac restriction by
TRIM5αAGM(tan), TRIM5αsq, or TRIM5αsp was not specifi-
cally affected by the presence of CsA (Fig. 2). These
observations provide further support for Cyp A enhancement
of the restriction of HIV-1 but not SIVmac infection by
TRIM5α variants. The data are consistent with the enhance-
ment of TRIM5α restriction by Cyp A being dependent upon
the interaction of Cyp A and the restricted viral capsid.
Effects of CA mutations that abolish Cyp A binding on HIV-1
restriction
Residues 89 and 90 on the HIV-1 CA make direct contacts
with Cyp A (Gamble et al., 1996). Previous studies have shown
that changing the glycine at position 89 to an alanine (G89A)
decreases the affinity of the interaction between CA and Cyp A
and leads to a significant decrease in HIV-1 infectivity in some
human cells (Braaten et al., 1996a; Franke and Luban, 1996;
Franke et al., 1994). However, this G89A mutant, which is not
restricted by TRIM-Cyp, can efficiently infect owl monkey cells
(Nisole et al., 2004; Sayah et al., 2004; Towers et al., 2003).
Some previous reports have shown that the G89A mutant can
partially escape restriction in Old World monkey cells
(Hatziioannou et al., 2004a; Owens et al., 2004); however, in
some Old World monkey cells, G89A still exhibited a low level
of infection (Towers et al., 2003). We examined the infection of
HeLa cells expressing TRIM5α variants by wild-type and
G89A HIV-1 in the presence or absence of CsA (Fig. 3). The
G89A mutant was inhibited by TRIM5αrh and other TRIM5α
variants, even after CsA treatment. Thus, TRIM5α retains the
ability to restrict HIV-1 viruses that do not bind Cyp A. The
G89A mutant was slightly less sensitive to restriction by several
of the TRIM5α variants than the wild-type HIV-1, particularly
considering the lower basal level of G89A infectivity in the
control cells. The relief of restriction by CsA treatment was
decreased for the G89A virus compared with that seen for wild-ifferent species. HeLa cells transduced with an empty control vector or vectors
r TRIM5αsp were incubated for 2 h in the presence of 0.1% ethanol or 5 μMCsA
ve cells was determined by FACS. The experiment was repeated twice with
Fig. 3. An HIV-1 CA mutant that does not bind Cyp A is still restricted by TRIM5α. HeLa cells transduced with an empty control vector or vectors expressing wild-
type TRIM5αrh, wild-type TRIM5αhu, the TRIM5αhu mutants K324N and R332P, or the human/rhesus chimera H(R323–332) were incubated for 2 h in the presence
of 0.1% ethanol or 5 μMCsA and then infected with either 14 kcpm or 56 kcpm of HIV-1-GFP or the G89A mutant HIV-1-GFP. The percentage of GFP-positive cells
was determined by FACS. The experiment was repeated with similar results.
116 M. Stremlau et al. / Virology 351 (2006) 112–120type HIV-1. These observations are consistent with the
contribution of Cyp A–CA binding to the positive effect that
Cyp A exerts on TRIM5α-mediated restriction.
Role of TRIM5α in Cyp A effects on HIV-1 replication
It has been suggested that Cyp A may protect the HIV-1
capsid from TRIM5αhu (Towers et al., 2003). If this hypothesis
is correct, then an HIV-1 virus that does not bind Cyp A should
be more susceptible to restriction in cells that express
TRIM5αhu than in cells that do not. To determine the effects
of TRIM5αhu expression on HIV-1 infection in the absence or
presence of CsA in a setting in which no endogenous
TRIM5αhu is present, we transduced Cf2Th canine thymocytes
with an empty control vector or with vectors expressing
TRIM5α variants. Canine cells do not express a TRIM5
ortholog (Song et al., 2005a). In empty control cells, theFig. 4. The effects of CsA treatment and TRIM5α expression on HIV-1 infectivity
vectors expressing TRIM5αrh or TRIM5αhu were incubated for 2 h in the presence o
GFP or the G89A mutant of HIV-1-GFP. The percentage of GFP-positive cells was
experiments are shown.addition of CsA caused a slight decrease in HIV-1 infectivity
(Fig. 4). The CsA effect and the decrease in HIV-1 infectivity
associated with TRIM5αhu expression were additive and
apparently independent. CsA treatment caused a slight increase
in the infectivity of HIV-1 in Cf2Th cells expressing TRIM5αrh.
The basal level of infection was decreased for the G89A mutant
compared with wild-type HIV-1. G89A did not escape
restriction by TRIM5αrh in canine cells. CsA treatment had
no effect on the infectivity of the G89A mutant (Fig. 4).
The role of FK506-binding proteins in TRIM5α restriction
FK506-binding proteins (FK506BP) are also members of the
immunophilin family of proteins and bind the immunosuppres-
sant drugs FK506 and rapamycin (Davies and Sanchez, 2005).
We studied the role of FK506-binding proteins in HIV-1-
restricted cells using rapamycin. The levels of HIV-1-GFPin canine cells. Cf2Th canine cells transduced with an empty control vector or
f 0.1% ethanol or 5 μM CsA and then infected with various amounts of HIV-1-
determined by FACS. The results of a typical experiment of three independent
Fig. 6. siRNA knock-down of TRIM5αrh and immunophilins in HIV-1-
restricted cells. Primary rhesus lung (PRL) cells were either mock-transfected or
transfected with 120 nM of the siRNAs targeting the indicated proteins. The
cells were then incubated with HIV-1-GFP. The percentage of GFP-positive cells
was determined by FACS. The results of a typical experiment are shown.
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compared with those in untreated control cells (Fig. 5).
Moreover, rapamycin treatment of the cell lines expressing
the TRIM5α variants did not relieve restriction in any
observable way (Fig. 5). Thus, the functions of FK506-binding
proteins that are inhibitable by rapamycin play no necessary role
in natural HIV-1 infection or in the TRIM5α restriction
pathway.
Effects of knocking down Cyp A expression with siRNA in
primary rhesus monkey cells
VSV-G-pseudotyped HIV-1 does not efficiently infect
primary rhesus lung (PRL) cells, which are derived from the
rhesus macaque, an Old World monkey species (Hofmann et
al., 1999). We tested the requirement for Cyp A in this
restriction by interfering with Cyp A expression using small
interfering RNA (siRNA). Transfection of an siRNA specific
for TRIM5α relieved the block to HIV-1-GFP by nearly 30-
fold, as previously reported (Stremlau et al., 2004). Transfec-
tion of a pool of four Cyp A-specific siRNAs partially relieved
restriction in the PRL cells, resulting in an 11-fold increase in
HIV-1 infectivity (Fig. 6). Other siRNAs that specifically
targeted cyclophilin M, cyclophilin 40, FK506BP2,
FK506BP4, and FK506BP5 did not enhance HIV-1 infectivity
in PRL cells (Fig. 6 and data not shown). These results are
consistent with Cyp A enhancing TRIM5αrh restriction of
HIV-1 infection.
Discussion
Host cell factors that modulate TRIM5α antiviral potency
have not been identified. TRIM5α retains its antiviral potency
in a broad range of mammalian cells, suggesting that any
cofactor must be highly conserved and ubiquitously expressed
(Javanbakht et al., 2005; Keckesova et al., 2004; Perez-
Caballero et al., 2005; Saenz et al., 2005). Cyp A, which
binds to the HIV-1 CA protein (Luban et al., 1993; Gamble et al.,
1996), meets these criteria. A recent report (Berthoux et al.,
2005), using approaches similar to those employed herein,
concluded that Cyp A was required for TRIM5α-mediatedFig. 5. Rapamycin does not relieve TRIM5α-mediated restriction. HeLa cells transd
wild-type TRIM5αhu, the TRIM5αhu mutants K324N and R332P, or the human/rhesu
20 nM rapamycin, or 20 nM rapamycin plus 5 μMCsA. The cells were incubated wit
was determined by FACS. The experiment was repeated with similar results.restriction of HIV-1 infection (Berthoux et al., 2005). Our
results, which are consistent with those presented by Berthoux
et al., suggest that Cyp A enhances but is not absolutely
required for the anti-HIV-1 activity of TRIM5α.
We found that blocking the interaction between Cyp A and
the HIV-1 CAwith the immunosuppressant drug CsA modestly
decreased TRIM5αrh antiviral potency. However, in human
cells that stably express TRIM5αrh, CsA treatment did not
restore the efficiency of HIV-1 infection to levels observed in
control cells not expressing TRIM5αrh. TRIM5αhu modestly
restricts HIV-1, and the determinants of potency have been
mapped to the v1 variable region in the B30.2 domain (Perez-
Caballero et al., 2005; Stremlau et al., 2005; Yap et al., 2005).
We tested two TRIM5αhu mutants, K324N and R332P, and one
human/rhesus TRIM5α chimera, H(R323–332), that have
previously been shown to restrict HIV-1 potently (Stremlau
et al., 2005). We found that the anti-HIV-1 activities of these
TRIM5αhu variants were more dependent on Cyp A func-
tion than that of wild-type TRIM5αrh. Thus, one variable
that can influence the contribution of Cyp A to restriction is
the particular restricting TRIM5α protein.
Capsids from SIVmac and MLV do not bind Cyp A; neither is
Cyp A required for efficient replication of these viruses (Franke
et al., 1994; Thali et al., 1994; Towers et al., 2003). We tested
whether Cyp A affected restriction of these viruses by TRIM5α.
Some slight enhancing effects of CsA treatment on SIVmacuced with an empty control vector or vectors expressing wild-type TRIM5αrh,
s chimera H(R323–332) were incubated for 2 h in the presence of 0.1% ethanol,
h either 4 kcpm or 32 kcpm of HIV-1-GFP. The percentage of GFP-positive cells
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not express a TRIM5α protein capable of restricting SIVmac
infection. Thus, the mild enhancement of SIVmac infection by
CsA treatment is apparently independent of TRIM5α-mediated
restriction. The ability of TRIM5α to restrict SIVmac and MLV
was not specifically dependent on Cyp A function. Certain
TRIM5α variants such as TRIM5αhu R332P and TRIM5αsp can
restrict infection by both HIV-1 and SIVmac. CsA treatment of
cells expressing TRIM5αhu R332P and TRIM5αsp partially
relieved the block to HIV-1 infection but had no effect on
SIVmac restriction. These results indicate that the contribution of
Cyp A to restriction is determined not only by the particular
TRIM5α protein but also by the restricted virus.
The interaction between Cyp A and the HIV-1 CA can be
disrupted by introducing changes in the Cyp A-binding site of
the CA protein (Braaten et al., 1996a, 1996b; Bukovsky et al.,
1997; Franke et al., 1994). We tested the ability of G89A, a
mutant that binds Cyp A much less efficiently than wild-type
HIV-1, to escape restriction by wild-type TRIM5αrh or
TRIM5αhu variants. There has been some inconsistency in the
literature regarding the extent to which HIV-1 CA mutants that
cannot bind Cyp A escape restriction by TRIM5α. Some reports
indicate that these mutants partially evade restriction in Old
World monkey cells (Hatziioannou et al., 2004a; Owens et al.,
2004), whereas one report claims that these mutants are still
sensitive to restriction (Towers et al., 2003). We found that the
G89A change that disrupts Cyp A binding to the HIV-1 CA
protein resulted in a virus that was slightly less sensitive to
restriction by TRIM5αrh or the TRIM5αhu variants compared
with the wild-type virus. Nonetheless, the G89A mutant
retained a substantial level of susceptibility to TRIM5α-
mediated restriction, even in the presence of CsA. Because of
the partial nature of this phenotype, the reported differences in
the sensitivity of HIV-1 capsid mutants to restriction may be due
to differences in the intrinsic level of replication of the HIV-1
CA mutants employed or in the level of TRIM5α expression in
the cells. The ability of CsA treatment to relieve HIV-1
restriction by some of the TRIM5αhu variants was diminished
for the G89A mutant compared with wild-type HIV-1 (Fig. 3).
This implies that the ability of the restricted virus capsid to bind
Cyp A contributes to the Cyp A enhancement of TRIM5α-
mediated restriction. Our observation that CsA treatment exerts
no effect on potent TRIM5α-mediated restriction of SIVmac and
N-MLV, which do not interact detectably with Cyp A, supports
a model in which Cyp A must bind the viral capsid to act as an
auxiliary factor for TRIM5α.
It has been hypothesized that the positive effects of Cyp A on
HIV-1 infection involve the prevention of recognition of the
HIV-1 capsid by a human antiviral factor (Sokolskaja et al.,
2004; Towers et al., 2003). If this hypothesis is correct,
TRIM5αhu is unlikely to be that antiviral factor. We knocked
down endogenous TRIM5αhu expression in human cells using
siRNA, but did not observe any enhancement of G89A
infectivity (data not shown). Furthermore, we expressed
TRIM5αhu in canine cells, which lack a TRIM5 gene (Song
et al., 2005a). In these cells, CsA treatment and TRIM5αhu
expression independently and additively decreased theinfectivity of wild-type HIV-1. The infectivity of the G89A
mutant was less than that of the wild-type HIV-1 both in the
control cells lacking TRIM5αrh and in the TRIM5αrh-
expressing cells. Thus, the positive effects of Cyp A binding
to the HIV-1 CA on HIV-1 replication do not depend upon
the presence of TRIM5αhu.
The immunophilins, including Cyp A, are members of a
large family of conserved proteins. We tested the role of the
FK506-binding proteins in TRIM5αrh-mediated HIV-1 restric-
tion by treating restricted cells with rapamycin. Rapamycin, a
competitive inhibitor of FK506-binding proteins, did not
abrogate restriction in any cell line tested. We also interfered
with the expression of several FK506-binding proteins, as well
as other members of the cyclophilin family such as cyclophilin
M and cyclophilin 40, using siRNA. Disruption of Cyp A
expression with siRNA partially relieved HIV-1 restriction in
primary rhesus monkey cells; however, none of the siRNA's
directed against the other immunophilins tested showed any
effects on HIV-1 infectivity in these cells.
Although our results do not support an absolute requirement
for Cyp A for TRIM5α-mediated restriction, they do point to a
role for Cyp A as an enhancer of TRIM5α activity against
viruses like HIV-1 that bind Cyp A. Cyp A appears to be more
important for restriction by some TRIM5α variants than by
wild-type TRIM5αrh. The mechanism of Cyp A enhancement
of TRIM5-mediated restriction requires further investigation.
Perhaps the cis/trans-isomerization activity of Cyp A alters the
conformation of the HIV-1 CA and exposes a higher-affinity
binding surface for TRIM5α. Alternatively, Cyp A might make
contacts directly with TRIM5α as part of a ternary complex
with CA, thus stabilizing TRIM5α binding. Cyp A may also
directly enhance the consequences of TRIM5α binding to the
restricted virus capsid, such as accelerated uncoating (Stremlau
et al., in press). Understanding the relationship between Cyp A
and TRIM5αhu may be important for developing novel
therapies that potentiate the ability of TRIM5αhu to restrict
HIV-1.
Materials and methods
Vectors and cell lines
Retroviral vectors encoding rhesus monkey TRIM5α,
human TRIM5α, squirrel monkey TRIM5α, African green
monkey (Cercopithecus aethiops pygerythrus) TRIM5α, Afri-
can green monkey (Cercopithecus aethiops tantalus) TRIM5α,
and spider monkey TRIM5α were created using the pLPCX
vector (Clontech), as previously described (Song et al., 2005a,
2005b; Stremlau et al., 2004). With the exception of TRIM5αrh
and TRIM5αhu, the TRIM5α proteins possess N-terminal
epitope tags derived from influenza virus hemagglutinin
(HA). In the TRIM5αrh and TRIM5αhu constructs, the HA
tag is at the C terminus. The human TRIM5α mutants, K324N
and R332P, were previously described and contain C-terminal
HA tags (Stremlau et al., 2005). A human TRIM5α chimera,
H(R323–332), in which residues 323–332 of human TRIM5α
have been replaced with the corresponding rhesus monkey
119M. Stremlau et al. / Virology 351 (2006) 112–120TRIM5α residues, was previously described and contains a
C-terminal HA tag (Stremlau et al., 2005). Cf2Th canine cells
expressing rhesus monkey and human TRIM5α proteins
containing C-terminal HA tags were previously described
(Javanbakht et al., 2005). All cell lines were maintained in
1 μg/ml puromycin (Sigma). TE671 cells were purchased
from the American Type Culture Collection and maintained as
suggested by the supplier.
Infection with viruses expressing green fluorescent protein
(GFP)
Recombinant HIV-1, SIVmac, N-MLV, B-MLV, and
Moloney MLV (NB-MLV) expressing GFP were prepared
as previously described (Hofmann et al., 1999; Perron et al.,
2004). HIV-1 and SIVmac were quantified by measuring
reverse transcriptase activity (RT) as described (Li et al.,
1992). N-MLV, B-MLV, and NB-MLV were normalized by
serial dilution on 293T cells as previously described (Perron
et al., 2004). For infections, 4 × 104 cells seeded in 24-well
plates were incubated for 2 h with 5 μM cyclosporine A
(Sigma) or 20 nM rapamycin (Sigma). Virus was added to the
cells and allowed to incubate an additional 16 h in the
presence of the drug. The cells were washed and returned to
culture for 48 h, and then subjected to FACS analysis with a
FACScan (Becton Dickinson).
RNA interference
The siRNA 3, which targets rhesus monkey TRIM5α, and
the control siRNA were previously described (Stremlau et al.,
2004). SmartPool siRNA (Dharmacon) was used to target
cyclophilin A (M-004979-00), cyclophilin M (M008888-00),
cyclophilin 40 (M-008256-00), FK506-binding protein 2 (M-
008945-00), FK506-binding protein 4 (M-006410-01), and
FK506-binding protein 5 (M004224-01). Primary rhesus lung
(PRL) cells (5 × 104) (Hofmann et al., 1999) were seeded in six-
well plates and transfected with 120 nM siRNA by using 10 μl of
oligofectamine (Invitrogen). After 48 h, the cells were reseeded
for infection with HIV-1-GFP, as described above.
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